Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
November 19, 2018 08:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
October 15, 2018 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 15, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President and Chief Executive Officer of Rafael Pharmaceuticals, Inc. will be presenting at the BIO Investor Forum 2018 in San Francisco...
Rafael Pharmaceuticals to Present at BIO Investor Forum 2018
October 09, 2018 08:55 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, Oct. 09, 2018 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc., a leader in the growing field of cancer metabolism-based therapeutics, today announced that Sanjeev Luther, its President...
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)
September 27, 2018 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., a global company providing biomarker and clonality test solutions for the fields of oncology and personalized molecular medicine®...
Actinium Announces New Clinical Trial to Study Effect of Actimab-A on Minimal Residual Disease in Postremission AML Patients
June 28, 2018 08:00 ET
|
Actinium Pharmaceuticals
Minimal Residual Disease is increasingly recognized as a primary driver of high AML relapse rate highlighting need for improved consolidation therapies Webcast to be held on July 10, 2018 at 8:00 AM...
Rafael Pharmaceuticals to Present New Data Validating Efficacy and Tolerability of CPI-613 in Treating Acute Myeloid Leukemia at the 23rd Congress of the European Hematology Association
June 14, 2018 10:12 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 14, 2018 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways...
Actinium Pharmaceuticals Announces Treatment of First Patient in Novel Combination Trial of Actimab-A Plus CLAG-M
June 13, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for...
Rafael Pharmaceuticals to Present at 2018 BIO International Convention
June 04, 2018 14:33 ET
|
Rafael Pharmaceutical Inc.
Newark, NJ, June 04, 2018 (GLOBE NEWSWIRE) -- Sanjeev Luther, President & CEO of Rafael Pharmaceuticals, Inc., will present the company’s clinical development strategy as Rafael prepares for its...
Actinium Pharmaceuticals Strengthens Targeted Myeloablation Focused Clinical Development Team with New Hires Including Experienced Bone Marrow Transplant Physician and Drug Developer Vijay Reddy, M.D., Ph.D. as Vice President, Clinical Development
April 18, 2018 07:30 ET
|
Actinium Pharmaceuticals
- Dr. Vijay Reddy joins Actinium with over 20 years of bone marrow transplant clinical experience including extensive product development experience at Pharmacyclics, an AbbVie Company, Medimmune and...
Actinium Pharmaceuticals Announces Collaborative Research Partnership with Astellas Leveraging Actinium’s AWE Platform Technology
March 28, 2018 08:00 ET
|
Actinium Pharmaceuticals
- Collaborative research agreement will utilize Actinium’s AWE Technology Platform to generate Actinium Radio-Conjugates on selected Astellas targeting agents - Actinium to perform preclinical...